Cochrane · systematic review · CD009620
Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer
Lawal, AO, Musekiwa, A, Grobler, L · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 10 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Interferon + chemotherapy versus chemotherapy alone for women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Population: Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Interferon + chemotherapy vs chemotherapy alone | HR 1.14 | 2 studies · 244 participants | Low Downgraded: risk of bias |
Progression‐free survival Interferon + chemotherapy vs chemotherapy alone | HR 1.43 [1.02, 2] | 2 studies · 244 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Adverse event (flu‐like symptoms) Interferon + chemotherapy vs chemotherapy alone | RR 6.49 [0.41, 102.25] | 2 studies · 230 participants | Low Downgraded: risk of bias |
Adverse event (fatigue) Interferon + chemotherapy vs chemotherapy alone | RR 1.17 [0.82, 1.68] | 1 study · 97 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Adverse event (neurotoxicity) Interferon + chemotherapy vs chemotherapy alone | RR 0.87 [0.57, 1.33] | 2 studies · 230 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Interferon versus observation alone for women with advanced (Stage II‐IV) epithelial ovarian cancer
Population: women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Interferon vs observation alone | HR 1.14 [0.84, 1.55] | 2 studies · 370 participants | Low Downgraded: risk of bias, imprecision |
Progression‐free survival Interferon vs observation alone | HR 0.99 [0.79, 1.24] | 2 studies · 370 participants | Low Downgraded: risk of bias, imprecision |
Adverse event (flu‐like symptoms) Interferon vs observation alone | RR 2.25 [1.73, 2.91] | 1 study · 293 participants | Low Downgraded: risk of bias, imprecision |
Adverse event (fatigue) Interferon vs observation alone | RR 1.54 [1.27, 1.88] | 1 study · 293 participants | Low Downgraded: risk of bias, imprecision |
Adverse event (nausea/ vomiting) Interferon vs observation alone | RR 1.21 [0.91, 1.62] | 1 study · 293 participants | Low Downgraded: risk of bias, imprecision |